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Abstract
Background: Metastatic germ cell tumor (mGCT) patients receiving chemotherapy 
have increased risk of life‐threatening venous thromboembolism (VTE). Identifying 
VTE risk factors may guide thromboprophylaxis in this highly curable population.
Methods: Data were collected from mGCT patients receiving first‐line platinum‐
based chemotherapy at 22 centers. Predefined variables included International Germ 
Cell Cancer Collaborative Group (IGCCCG) risk classification, long‐axis diameter 
   | 117TRAN eT Al.
1 |  INTRODUCTION
Germ cell tumors (GCTs) represent the most common solid can-
cer affecting young men.1 Even in the metastatic setting, GCT 
are highly curable, due to their extraordinary responsiveness 
to cisplatin‐based chemotherapy.1 Subsequently, much focus is 
now placed on survivorship, and minimizing treatment‐related 
toxicities while maintaining cure in these young men.
The increased risk of venous thromboembolism (VTE) 
in metastatic germ cell tumor (mGCT) patients is well rec-
ognized.2-8 While cisplatin‐based chemotherapy is highly 
curative, it may increase VTE risk,9 with an incidence of 
approximately 10% in mGCT patients.3-7 VTE can cause 
significant morbidity and even mortality.10 Hemorrhagic 
complications may occur in mGCT, due to treatment‐induced 
thrombocytopenia and the presence of choriocarcinoma.11 
There is a need to determine predictors of VTE risk in mGCT 
patients, in order to identify patients most likely to benefit 
from thromboprophylaxis.
Previously, in a small cohort, we reported that patients 
with large retroperitoneal lymph node (RPLN) metastases 
(>5 cm) were at significantly higher risk of VTE compared 
to those without (22% vs 5%, OR 5.26, P = .001). A similar 
but nonsignificant effect was observed in an underpowered 
validation cohort (14.2% vs 6%, OR 2.54, P = .16).3
The Global Germ Cell Collaborative Group (G3) is an 
international consortium committed to the management of 
GCT. This G3 study aimed to validate large RPLN metas-
tases as an independent risk factor for VTE in mGCT pa-
tients receiving first‐line platinum‐based chemotherapy. 
Secondary objectives aimed to determine the optimal cutoff 
for RPLN size as a predictor of VTE risk, to evaluate other 
potential risk factors, to assess the impact of VTE on over-
all survival (OS), and to explore the safety and benefit of 
thromboprophylaxis.
2 |  METHODS
The study protocol was circulated through the G3 group for 
expression of interest to participate. Institutional research 
ethics board approval was obtained.
2.1 | Study population
The cohort consists of men diagnosed with mGCT (Stage 
1S, 2, or 3 by American Joint Committee on Cancer [AJCC] 
stage classification12) treated with first‐line platinum‐based 
chemotherapy with curative intent between 1 January 2000 
and 31 December 2014. Patients with prior chemotherapy 
for GCT or history of secondary malignancy were excluded. 
Consecutive patients were enrolled from each site. Patients 
from the original study were not included.3
2.2 | Data collection
Retrospectively collected data were entered into case report 
forms. Baseline (pre‐chemotherapy) variables included age, 
presence of an indwelling vascular access device (VAD), hos-
pitalization (for any reason), primary tumor site, histology, 
AJCC stage, International Germ Cell Cancer Collaborative 
Group (IGCCCG) risk classification, and RPLN size. Baseline 
of largest retroperitoneal lymph node (RPLN), Khorana score, and use of indwelling 
vascular access device (VAD). VTE occurring at baseline, during chemotherapy and 
within 90 days, was analyzed.
Results: Data from 1135 patients were collected. Median age was 31 years (range 
10‐74). IGCCCG risk was 64% good, 20% intermediate, and 16% poor. VTE occurred 
in 150 (13%) patients. RPLN >3.5 cm demonstrated highest discriminatory accuracy 
for VTE (AUC 0.632, P < .001) and was associated with significantly higher risk of 
VTE in univariable analysis (22% vs 8%, OR 3.0, P < .001) and multivariable analy-
sis (OR 1.8, P = .02). Other significant risk factors included, Khorana score ≥3 (OR 
2.6, P = .008) and VAD use (OR 2.7, P < .001).
Conclusions: Large RPLN and VAD use are independent risk factors for VTE in 
mGCT patients receiving chemotherapy. VAD use should be minimized in this popu-
lation and thromboprophylaxis might be considered for large RPLN.
K E Y W O R D S
deep vein thrombosis, germ cell tumor, pulmonary embolism, testicular cancer, vascular access device, 
venous thromboembolism
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laboratory investigations were also recorded, including hemo-
globin, leukocyte count, and platelet count. Khorana score ≥3, 
a known VTE risk factor in cancer patients, was calculated.2 
Renal impairment was defined as creatinine clearance (CrCl) 
<75 mL/min (calculated using the Cockcroft Gault formula) 
at any point during chemotherapy as this has previously been 
associated with increased VTE risk.13 VTE was defined as 
either deep vein thrombosis (DVT) or pulmonary embolism 
(PE). Both symptomatic VTE and asymptomatic VTE de-
tected incidentally during routine imaging were included in 
this analysis. Superficial venous thrombosis or thrombophle-
bitis were not considered VTE events. VTE events must have 
occurred between diagnosis of metastatic disease and 90 days 
following chemotherapy completion. Where available, long‐
axis diameter measured in axial cross section (selected given 
its use in AJCC staging) of the largest RPLN metastasis from 
the pre‐chemotherapy CT scan was recorded. If unavailable, 
we used imaging reports to determine if the maximal diameter 
measured was >5 cm or ≤5 cm. Use of thromboprophylaxis 
and bleeding events were recorded. Last follow‐up date and 
survival status were collected.
2.3 | Statistical considerations
Categorical variables were compared between cohorts using 
Fisher's exact test and Kruskal‐Wallis test for two or greater 
than two variables, respectively. Continuous variables were 
compared using the Mann‐Whitney U test. Optimal cutoff for 
RPLN size in defining VTE risk was determined using the 
area under receiver operator characteristic curve (AUROC) 
and quantified as the previously described c‐statistic.14 Risk 
factors associated with VTE were evaluated using univari-
able logistic regression. Multivariable analysis was per-
formed using manual variable reduction; all variables with 
P < .1 in univariable analysis were included in the multivari-
able model individually, in addition to any variable showing 
evidence of confounding as previously described.15 Patients 
who received prolonged thromboprophylaxis (≥7 days) were 
excluded from these analyses; patients receiving short‐term 
thromboprophylaxis (<7  days) were included. An explora-
tory stratified analysis assessing large RPLN and VAD use 
was conducted using univariable logistic regression. Overall 
survival (OS) was assessed using the Cox proportional haz-
ards method; VTE was classified as a time‐dependent covari-
able. Statistical analyses were performed using SPSS version 
21 (IBM Corp). The threshold for statistical significance was 
a two‐sided P < .05 with no adjustment for multiple testing.
3 |  RESULTS
We identified 1135 patients with mGCT treated with first‐line 
platinum‐based chemotherapy across 22 sites in 10 countries. 
Table 1 describes the patient characteristics. VTE events oc-
curred in 150 (10%) patients. Of the potential VTE risk fac-
tors, Khorana score ≥3 was infrequent (7%), 33% of patients 
had baseline lactate dehydrogenase (LDH) >1.5× upper limit 
of normal (ULN), and 19% used VAD. The maximal long‐
axis diameter of the largest RPLN was available in 1011 
(89%) patients, and the median diameter in this group was 
3.0 cm, 25% had RPLN > 5 cm and 38% had RPLN >3.5 cm.
Table 2 details the VTE events, most occurred during or 
within 90 days of chemotherapy (64%). Intrabdominal DVT 
was the most common location (30%). Most VTE were symp-
tomatic (55%) and less than half required hospitalization 
(41%). There was one VTE‐related death.
In the subset with available long‐axis diameter, RPLN 
was associated with increased VTE risk when assessed as a 
continuous variable (OR 1.48, 95% CI 1.00, 2.18, P = .05). 
AUROC analysis determined that RPLN  >3.5  cm had 
greater discriminatory accuracy (AUC 0.632, P <  .0001) 
for VTE than RPLN > 5 cm (Figure S1A). Subsequently, 
3.5  cm was selected as the ideal cutoff for statistical 
analyses.
Table 3 describes results of the univariable analysis of 
VTE risk factors. RPLN >3.5 cm was a statistically signif-
icant risk factor; VTE occurred in 22% of RPLN >3.5  cm 
compared to 8% of RPLN ≤3.5. Other significant risk factors 
included IGCCCG poor risk, LDH >5× ULN, retroperitoneal 
primary, Khorana score ≥3, CrCl <75 mL/min, and VAD use. 
Hospital admission and BSA were not significant risk fac-
tors. Multivariable analysis confirmed large RPLN >3.5 cm, 
retroperitoneal primary, Khorana score  ≥3, and VAD as 
independent significant risk factors for VTE (Table 4). A 
sensitivity analysis was performed, excluding patients with 
VTE diagnosed between mGCT diagnosis and the start of 
chemotherapy. This demonstrated that both RPLN >3.5 cm 
(OR 2.19, 95% CI 1.36‐3.54, P = .001) and VAD (OR 4.93 
95% 2.90‐8.37, P < .001) remained significantly associated 
with VTE.
An exploratory stratified analysis for RPLN and VAD 
was conducted. In patients without VAD (n  =  559), 
RPLN >3.5 cm was strongly associated with VTE (OR 4.15, 
95% CI 2.16‐7.99, P < .001), whereas in patients with VAD 
(n = 218) the association was nonsignificant (OR 1.61 95% 
CI 0.80‐3.21, P = .18). The test for interaction between VAD 
and RPLN  >3.5  cm was statistically significant (P  =  .04), 
suggesting that in those with VAD, RPLN  >3.5  cm has a 
lesser effect on VTE risk.
There were 81 patients who received prolonged thrombo-
prophylaxis, mostly low molecular weight heparin (LMWH) 
(n  =  80). The VTE incidence in this thromboprophylaxis 
group was 15% (12 of 81) compared to 13% (138 of 1,054) 
in the non‐thromboprophylaxis group. VTE risk factors 
were more common in the thromboprophylaxis patients 
(RPLN >3.5 cm 65% vs 36%, P <  .001; VAD use 50% vs 
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T A B L E  1  Patient characteristics of the entire cohort (N = 1135)
Country
Canada 276 (24%)
Spain 260 (23%)
UK 152 (13%)
Switzerland 96 (8%)
Italy 77 (7%)
Germany 74 (7%)
Russia 69 (6%)
Australia 53 (5%)
Portugal 49 (4%)
France 29 (3%)
Age at diagnosis
Median (range) 31.1 (10.5‐74.0)
Primary site
Testis 1 046 (92%)
Retroperitoneal 19 (2%)
Mediastinal 33 (3%)
Other 36 (3%)
Unknown 1 (<1%)
Histology
Seminoma 308 (27%)
Non‐seminoma/Mixed 821 (72%)
Unknown 6 (1%)
AJCC stage (at time of chemotherapy)
1S 61 (5%)
2a 7 (1%)
2A 194 (17%)
2B 162 (14%)
2C 111 (10%)
3 578 (51%)
Unknown 22 (2%)
IGCCCG risk classification
Good 727 (64%)
Intermediate 224 (20%)
Poor 182 (16%)
Unknown 2 (<1%)
Chemotherapy regimenb
BEP 931 (82%)
EP 88 (8%)
VIP 26 (2%)
TIP 3 (<1%)
Other 86 (8%)
Body surface areac
Median 1.97
BSA >2 461 (44%)
(Continues)
Body mass indexc
Median 25.2
BMI >35 37 (4%)
Khorana score
1 714 (63%)
2 230 (20%)
3 71 (6%)
4 9 (1%)
Unknown 111 (10%)
Smoking status
Nonsmoker 538 (47%)
Current‐smoker 324 (29%)
Ex‐smoker 111 (10%)
Unknown 162 (14%)
Vascular access device inserted
Yes 218 (19%)
No 640 (56%)
Unknown 277 (24%)
Renal function during chemotherapyd
Median GFR (range) 120 mL/min 
(9‐309)
GFR <75 mL/min 64 (8%)
Hospitalizations
Yes 491 (43%)
No 367 (32%)
Unknown 277 (25%)
Coagulopathy or known past history VTE
Coagulopathy/VTE 14 (1%)
LDH
<1.5× ULN 735 (65%)
1.5‐5× ULN 270 (24%)
5‐10× ULN 58 (5%)
>10× ULN 40 (4%)
Unknown 32 (2%)
Retroperitoneal lymph node size
Median sizee 3.0 cm
RPLN >5 cm 288 (25%)
RPLN ≤5 cm 846 (74%)
Unknown 1 (1%)
RPLN >3.5 cm 431 (38%)
RPLN ≤3.5 cm 580 (52%)
Unknown 124 (10%)
Prolonged prophylactic anticoagulation >7 days
Yes 81 (7%)
No 1 035 (91%)
T A B L E  1  (Continued)
(Continues)
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17%, P < .001). Median duration of thromboprophylaxis was 
45 days (range 8‐239), while the median duration of chemo-
therapy was 65  days (range 33‐184). An additional 48 pa-
tients received short‐term (<7 days) prophylaxis prescribed 
for inpatient hospital admissions.
In the entire cohort, there were 17 documented bleeding 
events (1.5%), resulting in nine hospitalizations, with eight 
requiring intervention (Table S1B). There were two bleed-
ing‐related deaths, neither were receiving anticoagulation. 
There were no bleeding events identified in those receiving 
thromboprophylaxis. Two bleeding events occurred in the 
140 patients who received therapeutic anticoagulation for 
VTE (1.4%).
After a median follow‐up of 49  months, there were 95 
deaths. The 2‐year OS was 99% for good, 95% for interme-
diate, and 71% for poor IGCCCG prognosis categories. In 
univariable OS analysis, VTE, RPLN >3.5 cm, and IGCCCG 
risk group were significant prognostic factors, while in multi-
variable analysis, only IGCCCG risk group remained signif-
icant (Table S1C).
4 |  DISCUSSION
This multinational G3 consortium study was designed to 
validate large RPLN as a VTE risk factor in mGCT patients 
receiving chemotherapy. We found that large RPLN in-
dependently predicted risk of VTE, and a cutoff of 3.5 cm 
allowed for greater discriminatory accuracy and superior pre-
dictive accuracy compared to our original cutoff of 5  cm.3 
Our data support large RPLN as a relevant biomarker that 
should be considered when assessing VTE risk in this patient 
population.
Several publications have identified large RPLN as a 
risk factor for VTE in mGCT patients.3-6 Gizzi et al6 re-
ported that enlarged RPLN was significantly associated 
with VTE in multivariable analyses. Similarly, a single‐in-
stitution Austrian study found RPLN >5 cm was a strong 
predictor of VTE (stratified HR 3.29, P = .002).5 Our study 
is the largest cohort to date of chemotherapy‐treated mGCT 
analyzed for VTE and confirms large RPLN as a signifi-
cant risk factor.
We also identified VAD use as a significant VTE risk 
factor. In our cohort, 19% of patients utilized VADs, with 
29% subsequently developing VTE. Prior studies, hin-
dered by heterogeneous cohorts and small sample sizes, 
estimated the incidence of VAD‐associated VTE in mGCT 
patients to be 8%‐59%.7,16-18 The increased VTE risk asso-
ciated with VAD use in our study suggests that routine in-
sertion of VADs to facilitate chemotherapy administration 
should be avoided. In situations where VAD use is neces-
sary (eg, poor venous access, patient preference), throm-
boprophylaxis could be considered as a means of reducing 
VAD‐associated VTE.
Other significant VTE risk factors were also identified. 
Khorana score  ≥3, consistent with previous reports, was 
associated with increased risk;2,3 however, it only captured 
20 (16%) VTE events, restricting its utility in this patient 
group. Renal impairment, defined by CrCl  <75  mL/min, 
was also associated with increased risk; however, as it is 
logged at any point during chemotherapy (and not at base-
line), its utility as a predictive risk factor is limited. Only 15 
patients had an extragonadal retroperitoneal primary tumor 
and its role as a VTE risk factor should be interpreted with 
caution. Unexpectedly, hospitalizations were more frequent 
than expected (43%) but not a significant VTE risk factor. 
Unknown 19 (2%)
Venous thromboembolism (VTE)  
Occurrence of VTE 150 (10%)
aIdentified as stage 2 but further sub‐classification unavailable. 
bBEP = Bleomycin, Etoposide, Cisplatin; BSA = Body Surface Area; 
EP = Etoposide, Cisplatin; VIP = Etoposide, Ifosfamide, Cisplatin; 
TIP = Paclitaxel, Ifosfamide, Cisplatin. 
cAvailable for 1051 (93%) of patients. 
dAvailable for 764 (70%) of patients. 
eBased upon for 1011 (89%) of patients with actual measurement recorded. 
T A B L E  1  (Continued)
T A B L E  2  VTE characteristics
Total number of VTE 150
Timing of VTE diagnosis
Immediately prior to chemotherapy initiation 52 (35%)
During chemotherapy 78 (52%)
Immediately following chemotherapy completion 18 (12%)
Post‐chemotherapy, Postoperative setting 2 (1%)
Location of VTE
Abdominal DVT (incl. IVC, iliac veins) 45 (30%)
Upper limb DVT (incl. subclavian, brachial veins) 11 (7%)
Lower limb DVT (incl. femoral vein) 27 (18%)
Pulmonary Embolus 42 (28%)
Other 4 (3%)
Vascular Access Device associated 21 (14%)
Presentation of VTE
Symptomatic 83 (55%)
Incidental on imaging 39 (26%)
Unknown 28 (19%)
Complications of VTE
Death due to VTE 1 (1%)
Hospitalization due to VTE 62 (41%)
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T A B L E  3  Risk factors for VTE (univariable analysis)
Factor
No. of patients
N = 1 054a
No. of VTE (%)
N = 138 (13%) OR 95% CI P
RPLN 3.5 cm cutoffb          
RPLN ≤3.5 cm 931 42 (8%) — — —
RPLN >3.5 cm 378 82 (22%) 2.98 2.04, 4.34 <.001
RPLN 5 cm cutoffc          
RPLN ≤5 cm 810 84 (10%) — — —
RPLN >5 cm 243 54 (22%) 2.6 1.77, 3.81 <.001
Primary sited          
Testicular primary 979 118 (12%) — — —
Mediastinal primary 27 6 (22%) 2.16 0.78, 5.99 .14
Retroperitoneal primary 15 6 (40%) 5.76 1.97, 16.82 .001
IGCCCG Risk Classificatione          
Good prognosis 693 64 (9%) — — —
Intermediate prognosis 204 31 (15%) 1.72 1.08, 2.74 .02
Poor prognosis 155 43 (28%) 3.26 2.06, 5.17 <.001
LDH categoriesf          
<1.5× ULN 702 61 (9%) — — —
1.5‐ 5× ULN 244 50 (20%) 2.55 1.68, 2.74 <.001
5‐10× ULN 48 13 (27%) 3.61 1.78, 7.32 <.001
>10× ULN 30 9 (30%) 4.68 1.95, 11.22 .001
LDH cutofff          
<5× ULN 946 111 (12%) — — —
>5× ULN 78 22 (28%) 2.92 1.70‐5.02 <.001
Khorana scoreg          
0‐2 882 105 (12%) — — —
>3 66 20 (30%) 3.19 1.80, 5.64 <.001
Hospitalizationh          
No 359 40 (11%) — — —
Yes 413 64 (15%) 1.44 0.94‐2.19 .1
BSAi          
<2 621 83 (13%) — — —
>2 414 52 (13%) 0.9 0.62‐1.31 .58
Vascular access devicej          
No 602 58 (10%)   — —
Yes 177 51 (29%) 3.46 2.22, 5.40 <.001
Renal functionk          
CrCl >75 mL/min 668 89 (13%) — — —
CrCl <75 mL/min 51 16 (31%) 3.48 1.87, 6.49 <.001
aExcludes patients who received prophylactic anticoagulation. 
bUnknown in 123 patients. 
cUnknown in 1 patient. 
dUnknown or other site in 33 patients. 
eUnknown in 2 patients. 
fUnknown in 30 patients. 
gUnknown in 106 patients. 
hUnknown in 277 patients. 
iUnknown in 81 patients. 
jUnknown in 275 patients. 
kUnknown in 335 patients. 
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Some participating centers regularly administered chemo-
therapy regimens such as bleomycin (BEP) as an inpatient 
and given these patients are not acutely unwell, they are 
unlikely to harbor the same VTE risks as other hospitalized 
patients.
A recent study by the Spanish Germ Cell Group sug-
gested that the occurrence of VTE in mGCT patients was 
associated with poorer progression‐free survival (PFS; HR 
2.29, P = .02) and OS (HR 5.14, P < .001).4 While Bezan 
et al reported a fourfold increased risk of death with onset 
of VTE (HR 4.0, P =  .03), this association did not persist 
in multivariable analyses after adjusting for tumor stage.5 In 
our study, VTE was associated with significantly poorer OS 
in univariable analysis (2‐year OS 85% vs 95%, HR 2.84, 
P < .001), but this was not confirmed in multivariable anal-
ysis (HR 1.51, P = .10). As such, we were unable to validate 
VTE as an independent risk factor for OS.
While our study confirmed that large RPLN metastases 
predict for higher risk of VTE in mGCT, the role of throm-
boprophylaxis in these patients is unproven. One retrospec-
tive study demonstrated a twofold reduction in VTE with 
thromboprophylaxis, yet subsequent multivariable analyses 
using a matching model failed to show statistical significance 
(OR 0.50, P = .09).6 Others have found no difference in VTE 
events with this approach.19 Given the retrospective nature of 
our study and the selection bias involved in analyzing patients 
who received thromboprophylaxis, we cannot comment on the 
safety nor efficacy of thromboprophylaxis in mGCT patients.
Ideally, a prospective, randomized clinical trial would be 
conducted to demonstrate the benefit of thromboprophylaxis 
in mGCT with RPLN >3.5 cm. Currently, ASCO guidelines 
recommend against routine thromboprophylaxis for can-
cer outpatients receiving chemotherapy,20 with the only ex-
ception being multiple myeloma where the risk of VTE is 
estimated to be 12%‐36% when receiving thalidomide and 
dexamethasone.21 Our data demonstrate the risk of VTE in 
mGCT patients with RPLN >3.5 cm (22%) to be compara-
ble, and subsequently, thromboprophylaxis may have a role 
in these patients. While some centers have already adopted 
routine thromboprophylaxis in this high‐risk patient popula-
tion,6,22 given the risks of catastrophic bleeding in this cur-
able population, a trial is required to determine if this is in our 
patients' best interest.
Our study has several limitations. Missing data were evi-
dent for multiple risk factors; however, our large sample size 
provided adequate power to overcome this. Our study did not 
include VTE events occurring beyond 90 days of completing 
chemotherapy, despite some data suggesting VTE risk per-
sists beyond this period.6,7 We included patients receiving 
short‐term thromboprophylaxis in VTE risk analyses, prag-
matically defining a cutoff of 7 days, as we did not believe 
this short duration would significantly impact VTE risk. 
Maximal RPLN diameter was assessed by individual inves-
tigators rather than by central review, although interobserver 
variability was minimized through the provision of training 
materials to each site. Finally, as with any retrospective study, 
there is significant heterogeneity in practice patterns.
In conclusion, our large multinational study examining 
risk factors for VTE in mGCT patients receiving first‐line 
platinum‐based chemotherapy confirmed large RPLN as 
an independent risk factor for VTE and identified 3.5  cm 
as the optimal cutoff to identify patients who may benefit 
from thromboprophylaxis. We have also confirmed VAD use 
as a significant risk factor for VTE. Our findings have im-
portant clinical implications. Routine VAD insertion should 
be avoided in mGCT patients receiving chemotherapy, 
and thromboprophylaxis may have a role for patients with 
RPLN >3.5 cm and those where use of VAD is necessary, 
although prospective trials are desperately needed.
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